Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in previously treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer (BC): Patient-reported outcomes (PROs) from the TROPION-Breast01 study Meeting Abstract
| Authors: | Pernas, S.; Im, S. A.; Hattori, M.; Xu, B.; Wang, S.; Lu, Y. S.; Borges, G.; Tsurutani, J.; Jhaveri, K. L.; Zhang, Q. Y.; De Laurentiis, M.; Martinez-JanĚez, N.; Hamilton, E. P.; Rugo, H. S.; Kalinsky, K.; Tolaney, S. M.; Shi, L.; Khan, S. S.; Zhu, Y.; Bardia, A. |
| Abstract Title: | Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in previously treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer (BC): Patient-reported outcomes (PROs) from the TROPION-Breast01 study |
| Meeting Title: | 2024 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 42 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2024 May 31-Jun 4 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2024-06-01 |
| Language: | English |
| ACCESSION: | WOS:001275557400116 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2024.42.16_suppl.1006 |
| Notes: | Meeting Abstract: 1006 -- Source: Wos |
